3,345 IQVIA Holdings Inc. $IQV Shares Sold by Formuepleje A S

Formuepleje A S lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 14.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,920 shares of the medical research company’s stock after selling 3,345 shares during the period. Formuepleje A S’s holdings in IQVIA were worth $5,355,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Ascentis Independent Advisors acquired a new position in IQVIA in the first quarter valued at about $25,000. Financial Freedom LLC acquired a new stake in IQVIA during the first quarter worth about $25,000. Compass Financial Management LLC acquired a new stake in IQVIA during the second quarter worth about $27,000. Elevation Wealth Partners LLC grew its stake in IQVIA by 218.8% during the second quarter. Elevation Wealth Partners LLC now owns 153 shares of the medical research company’s stock worth $30,000 after buying an additional 105 shares in the last quarter. Finally, Caitlin John LLC bought a new position in IQVIA in the 2nd quarter valued at about $31,000. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Price Performance

IQVIA stock traded up $7.58 during midday trading on Thursday, reaching $269.59. The company’s stock had a trading volume of 345,078 shares, compared to its average volume of 1,698,641. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $277.40. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The business has a 50-day moving average price of $259.41 and a 200-day moving average price of $211.71. The stock has a market cap of $44.38 billion, a PE ratio of 33.44, a price-to-earnings-growth ratio of 2.26 and a beta of 1.17.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%. The firm had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. During the same quarter in the previous year, the firm earned $2.81 earnings per share. The business’s quarterly revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 11.56 EPS for the current year.

Insider Buying and Selling at IQVIA

In related news, insider James G. Berkshire sold 2,668 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the transaction, the insider owned 10,890 shares of the company’s stock, valued at $2,845,883.70. This represents a 19.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Bhavik Patel sold 1,855 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the sale, the insider owned 1,348 shares in the company, valued at $317,143.96. This represents a 57.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 15,581 shares of company stock worth $3,796,021 over the last 90 days. 1.70% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on IQV. Truist Financial reaffirmed a “buy” rating and set a $329.00 price target (up from $300.00) on shares of IQVIA in a report on Monday, September 28th. Barclays lifted their price objective on shares of IQVIA from $275.00 to $300.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. William Blair raised shares of IQVIA to a “strong-buy” rating in a research note on Tuesday, July 28th. BMO Capital Markets boosted their price objective on shares of IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. Finally, Royal Bank Of Canada upped their target price on IQVIA from $247.00 to $319.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 29th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $276.00.

About IQVIA

IQVIA Holdings Inc (NYSE: IQV) is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop products, manage clinical trials, understand healthcare markets and improve commercial performance.

IQVIA’s offerings include clinical research and trial management, real-world data and evidence, healthcare analytics, technology platforms, consulting, and commercial services such as sales support and patient engagement.